Abiopharma

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

New Form 10-Q - Fulcrum Therapeutics, Inc. Filed: 2025-10-29 AccNo: 0001193125-25-254633 Size: 10 MB

New Form 10-Q - AMARIN CORP PLC\UK Filed: 2025-10-29 AccNo: 0001193125-25-254621 Size: 12 MB

(30% Negative) IONIS PHARMACEUTICALS, INC. (IONS) Reports Q4 2025 Financial Results

(30% Negative) AMARIN CORP PLC\UK (AMRN) Reports Q4 2025 Financial Results

(90% Positive) Fulcrum Therapeutics, Inc. (FULC) Announces Enrollment Update for complete Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

(70% Positive) AVALO THERAPEUTICS, INC. (AVTX) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(30% Negative) AXOGEN, INC. (AXGN) Reports Q4 2025 Financial Results

(30% Negative) Bausch & Lomb Corp (BLCO) Reports Q4 2025 Financial Results

(80% Positive) CABALETTA BIO, INC. (CABA) Files Form 8-K

New Form 6-K - Tiziana Life Sciences Ltd Filed: 2025-10-29 AccNo: 0001213900-25-103246 Size: 42 KB

New Form 6-K - OKYO Pharma Ltd Filed: 2025-10-29 AccNo: 0001493152-25-019989 Size: 42 KB

(10% Negative) STEPAN COMPANY (SCL) Reports Q4 2025 Financial Results

Stepan Increases Quarterly Cash Dividend, Marking the 58th Consecutive Year of Increases